Person · CIK 1683607

Bonnie L Bassler

Director at Royalty Pharma, Regeneron Pharmaceuticals and Cidara Therapeutics

Earlier: Kaleido Biosciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$22.3M

Noticed on Form 144$9.4M

Bought on Form 4$0

Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Royalty Pharma RPRX	Class A Ordinary Shares	Directly	79,823	Sep 30, 2026 · Filing · EDGAR
Regeneron Pharmaceuticals REGN	Common Stock	Directly	1,703	Jan 7, 2026 · Filing · EDGAR
Regeneron Pharmaceuticals REGN	Non-Qualified Stock Option (right to buy) exercise $374.12, expires Jan 2, 2030, into Common Stock	Directly	2,861	Jan 7, 2026 · Filing · EDGAR
Kaleido Biosciences	Stock Option (Right to Buy) exercise $7.44, expires Jun 29, 2031, into Common Stock	Directly	15,000	Jun 30, 2021 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q1 2026	$1.2M	$1.2M
Q4 2025	$570K	$570K
Q3 2024	$1.7M	$1.7M
Q2 2024	$1.6M	$1.6M
Q1 2024	$2.4M	$2.4M
Q4 2023	$531K	$531K
Q3 2023	$1.4M	$1.4M
Q1 2023	$1.8M	Not machine-readable
Q4 2022	$170K	Not machine-readable
Q3 2022	$2.2M	Not machine-readable
Q2 2022	$899K	Not machine-readable
Q1 2022	$868K	Not machine-readable
Q3 2021	$3.8M	Not machine-readable
Q2 2020	$3.1M	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Regeneron Pharmaceuticals REGN · RBC Capital Markets · 10b5-1 plan adopted May 2, 2025 · 2 notices
Jan 7, 2026	1,500 · ~$1.2M	Jan 7, 2026	Sold as noticed Sold 1,500 at $800.00 on Jan 7 · $1.2M Form 4	Filing · EDGAR
Nov 20, 2025	760 · ~$570K	Nov 20, 2025	Sold as noticed Sold 760 at $750.00 on Nov 20 · $570K Form 4	Filing · EDGAR
Regeneron Pharmaceuticals REGN · RBC Wealth Management · 10b5-1 plan adopted Feb 27, 2024 · 4 notices
Aug 15, 2024	756 · ~$885K	Aug 15, 2024	Sold as noticed Sold 756 at $1,170.00 on Aug 15 · $885K Form 4	Filing · EDGAR
Aug 2, 2024	756 · ~$843K	Aug 2, 2024	Sold as noticed Sold 756 at $1,115.00 on Aug 2 · $843K Form 4	Filing · EDGAR
Jun 24, 2024	756 · ~$803K	Jun 24, 2024	Sold as noticed Sold 756 at $1,062.00 on Jun 24 · $803K Form 4	Filing · EDGAR
Jun 5, 2024	827 · ~$836K	Jun 5, 2024	Sold as noticed Sold 827 at $1,011.00 on Jun 5 · $836K Form 4	Filing · EDGAR
Regeneron Pharmaceuticals REGN · RBC Wealth Management · No 10b5-1 plan stated · 1 notice
Feb 26, 2024	854 · ~$836K	Feb 26, 2024	Sold as noticed Sold 854 at $979.25 on Feb 26 · $836K Form 4	Filing · EDGAR
Regeneron Pharmaceuticals REGN · RBC Wealth Management · 10b5-1 plan adopted May 11, 2023 · 4 notices
Jan 30, 2024	827 · ~$793K	Jan 30, 2024	Sold as noticed Sold 827 at $959.00 on Jan 30 · $793K Form 4	Filing · EDGAR
Jan 3, 2024	826 · ~$755K	Jan 3, 2024	Sold as noticed Sold 826 at $914.00 on Jan 3 · $755K Form 4	Filing · EDGAR
Dec 13, 2023	610 · ~$531K	Dec 13, 2023	Sold as noticed Sold 610 at $870.00 on Dec 13 · $531K Form 4	Filing · EDGAR
Aug 21, 2023	853 · ~$707K	Aug 21, 2023	Sold as noticed Sold 853 at $829.00 on Aug 21 · $707K Form 4	Filing · EDGAR
Regeneron Pharmaceuticals REGN · RBC Capital Markets · 10b5-1 plan adopted May 11, 2023 · 1 notice
Aug 10, 2023	853 · ~$673K	Aug 10, 2023	Sold as noticed Sold 853 at $789.00 on Aug 10 · $673K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 14 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,240 at $818.00 on Mar 24, 2023 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,021 at $779.00 on Feb 3, 2023 · $795K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 218 at $779.00 on Dec 8, 2022 · $170K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 609 at $741.00 on Sep 9, 2022 · $451K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,279 at $686.99 on Sep 8, 2022 · $879K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,279 at $705.00 on Sep 8, 2022 · $902K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,240 at $725.00 on Apr 7, 2022 · $899K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,240 at $700.00 on Mar 30, 2022 · $868K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,219 at $630.00 on Aug 16, 2021 · $768K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2,559 at $600.00 on Aug 5, 2021 · $1.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2,558 at $575.00 on Jul 1, 2021 · $1.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 11 at $631.37 on Jun 19, 2020 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2,548 at $630.01 on Jun 19, 2020 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2,559 at $600.00 on Jun 5, 2020 · $1.5M (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Royalty Pharma RPRX Director · filings 2020 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 30, 2026	Grant or award from the company	+642	$58.41	$37K	79,823 direct	Filing · EDGAR
Jun 30, 2026	Grant or award from the company	+689	$54.40	$37K	79,181 direct	Filing · EDGAR
Jun 5, 2026	Grant or award from the company	+4,545			78,492 direct	Filing · EDGAR
Mar 31, 2026	Grant or award from the company	+815	$45.98	$37K	73,947 direct	Filing · EDGAR
Dec 31, 2025	Grant or award from the company	+967	$38.74	$37K	73,132 direct	Filing · EDGAR
Sep 30, 2025	Grant or award from the company	+1,047	$35.79	$37K	72,165 direct	Filing · EDGAR
Jun 30, 2025	Grant or award from the company	+1,064	$35.24	$37K	71,118 direct	Filing · EDGAR
May 13, 2025	Grant or award from the company	+7,614			70,054 direct	Filing · EDGAR
Mar 31, 2025	Grant or award from the company	+1,141	$32.87	$37K	62,440 direct	Filing · EDGAR
Dec 31, 2024	Grant or award from the company	+1,503	$24.94	$37K	61,299 direct	Filing · EDGAR
Sep 30, 2024	Grant or award from the company	+1,342	$27.92	$37K	59,796 direct	Filing · EDGAR
Jun 28, 2024	Grant or award from the company	+1,399	$26.80	$37K	58,454 direct	Filing · EDGAR
Jun 7, 2024	Grant or award from the company	+9,293			57,055 direct	Filing · EDGAR
Mar 28, 2024	Grant or award from the company	+1,240	$30.23	$37K	47,762 direct	Filing · EDGAR
Dec 29, 2023	Grant or award from the company	+1,353	$27.71	$37K	46,522 direct	Filing · EDGAR
Sep 29, 2023	Grant or award from the company	+1,384	$27.08	$37K	45,169 direct	Filing · EDGAR
Jun 30, 2023	Grant or award from the company	+1,208	$31.03	$37K	43,785 direct	Filing · EDGAR
Jun 23, 2023	Grant or award from the company	+7,747			42,577 direct	Filing · EDGAR
Mar 31, 2023	Grant or award from the company	+1,049	$35.73	$37K	34,830 direct	Filing · EDGAR
Dec 30, 2022	Grant or award from the company	+943	$39.76	$37K	33,781 direct	Filing · EDGAR
Sep 30, 2022	Grant or award from the company	+913	$41.06	$37K	32,838 direct	Filing · EDGAR
Jun 30, 2022	Grant or award from the company	+903	$41.52	$37K	31,925 direct	Filing · EDGAR
Jun 24, 2022	Grant or award from the company	+6,328			31,022 direct	Filing · EDGAR
Mar 31, 2022	Grant or award from the company	+964	$38.87	$37K	24,694 direct	Filing · EDGAR
Dec 31, 2021	Grant or award from the company	+958	$39.11	$37K	23,730 direct	Filing · EDGAR
Sep 30, 2021	Grant or award from the company	+992	$37.80	$37K	22,772 direct	Filing · EDGAR
Jun 30, 2021	Grant or award from the company	+871	$43.04	$37K	21,780 direct	Filing · EDGAR
Jun 25, 2021	Grant or award from the company	+5,726			20,909 direct	Filing · EDGAR
Mar 31, 2021	Grant or award from the company	+816	$45.90	$37K	15,183 direct	Filing · EDGAR
Dec 31, 2020	Grant or award from the company	+820	$45.69	$37K	14,367 direct	Filing · EDGAR
Sep 30, 2020	Grant or award from the company	+910	$41.17	$37K	13,547 direct	Filing · EDGAR
Jun 30, 2020	Grant or award from the company	+137	$48.00	$7K	12,637 direct	Filing · EDGAR
Jun 18, 2020	Grant or award from the company	+12,500			12,500 direct	Filing · EDGAR

Regeneron Pharmaceuticals REGN Director · filings 2016 to 2026 · sold $22.3M · $9.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 7, 2026	Option or RSU exercised or converted	+1,500	$374.12	$561K	3,203 direct	Filing · EDGAR
Jan 7, 2026	Sale under a 10b5-1 plan	−1,500	$800.00	$1.2M	1,703 direct	Filing · EDGAR
Jan 7, 2026	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−1,500			2,861 direct	Filing · EDGAR
Jan 2, 2026	Grant or award from the company	+155			1,703 direct	Filing · EDGAR
Jan 2, 2026	Grant or award from the company Non-Qualified Stock Option (right to buy)	+1,962			1,962 direct	Filing · EDGAR
Nov 20, 2025	Option or RSU exercised or converted	+760	$371.40	$282K	2,308 direct	Filing · EDGAR
Nov 20, 2025	Sale under a 10b5-1 plan	−760	$750.00	$570K	1,548 direct	Filing · EDGAR
Nov 20, 2025	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−760			756 direct	Filing · EDGAR
Jan 2, 2025	Grant or award from the company	+166			1,548 direct	Filing · EDGAR
Jan 2, 2025	Grant or award from the company Non-Qualified Stock Option (right to buy)	+1,958			1,958 direct	Filing · EDGAR
Aug 15, 2024	Option or RSU exercised or converted	+756	$371.40	$281K	2,138 direct	Filing · EDGAR
Aug 15, 2024	Sale under a 10b5-1 plan	−756	$1,170.00	$885K	1,382 direct	Filing · EDGAR
Aug 15, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−756			1,516 direct	Filing · EDGAR
Aug 2, 2024	Option or RSU exercised or converted	+756	$371.40	$281K	2,138 direct	Filing · EDGAR
Aug 2, 2024	Sale under a 10b5-1 plan	−756	$1,115.00	$843K	1,382 direct	Filing · EDGAR
Aug 2, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−756			2,272 direct	Filing · EDGAR
Jun 24, 2024	Option or RSU exercised or converted	+756	$371.40	$281K	2,138 direct	Filing · EDGAR
Jun 24, 2024	Sale under a 10b5-1 plan	−756	$1,062.00	$803K	1,382 direct	Filing · EDGAR
Jun 24, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−756			3,028 direct	Filing · EDGAR
Jun 5, 2024	Option or RSU exercised or converted	+827	$380.95	$315K	2,209 direct	Filing · EDGAR
Jun 5, 2024	Sale under a 10b5-1 plan	−827	$1,011.00	$836K	1,382 direct	Filing · EDGAR
Jun 5, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−827			0 direct	Filing · EDGAR
Feb 26, 2024	Option or RSU exercised or converted	+854	$391.92	$335K	2,236 direct	Filing · EDGAR
Feb 26, 2024	Open-market or private sale	−854	$979.25	$836K	1,382 direct	Filing · EDGAR
Feb 26, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−854			0 direct	Filing · EDGAR
Jan 30, 2024	Option or RSU exercised or converted	+827	$380.95	$315K	2,209 direct	Filing · EDGAR
Jan 30, 2024	Sale under a 10b5-1 plan	−827	$959.00	$793K	1,382 direct	Filing · EDGAR
Jan 30, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−827			827 direct	Filing · EDGAR
Jan 3, 2024	Option or RSU exercised or converted	+826	$380.95	$315K	2,208 direct	Filing · EDGAR
Jan 3, 2024	Sale under a 10b5-1 plan	−826	$914.00	$755K	1,382 direct	Filing · EDGAR
Jan 3, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−826			1,654 direct	Filing · EDGAR
Jan 2, 2024	Grant or award from the company	+135			1,382 direct	Filing · EDGAR
Jan 2, 2024	Grant or award from the company Non-Qualified Stock Option (right to buy)	+1,607			1,607 direct	Filing · EDGAR
Dec 13, 2023	Option or RSU exercised or converted	+610	$376.69	$230K	1,857 direct	Filing · EDGAR
Dec 13, 2023	Sale under a 10b5-1 plan	−610	$870.00	$531K	1,247 direct	Filing · EDGAR
Dec 13, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−610			0 direct	Filing · EDGAR
Aug 21, 2023	Option or RSU exercised or converted	+853	$391.92	$334K	2,100 direct	Filing · EDGAR
Aug 21, 2023	Sale under a 10b5-1 plan	−853	$829.00	$707K	1,247 direct	Filing · EDGAR
Aug 21, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−853			854 direct	Filing · EDGAR
Aug 10, 2023	Option or RSU exercised or converted	+853	$391.92	$334K	2,100 direct	Filing · EDGAR
Aug 10, 2023	Sale under a 10b5-1 plan	−853	$789.00	$673K	1,247 direct	Filing · EDGAR
Aug 10, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−853			1,707 direct	Filing · EDGAR
Mar 24, 2023	Option or RSU exercised or converted	+1,240	$380.95	$472K	2,487 direct	Filing · EDGAR
Mar 24, 2023	Sale under a 10b5-1 plan	−1,240	$818.00	$1M	1,247 direct	Filing · EDGAR
Mar 24, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−1,240			2,480 direct	Filing · EDGAR
Feb 3, 2023	Option or RSU exercised or converted	+1,021	$380.95	$389K	2,268 direct	Filing · EDGAR
Feb 3, 2023	Sale under a 10b5-1 plan	−1,021	$779.00	$795K	1,247 direct	Filing · EDGAR
Feb 3, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−1,021			3,720 direct	Filing · EDGAR
Jan 3, 2023	Grant or award from the company	+165			1,247 direct	Filing · EDGAR
Jan 3, 2023	Grant or award from the company Non-Qualified Stock Option (right to buy)	+1,929			1,929 direct	Filing · EDGAR
Dec 8, 2022	Option or RSU exercised or converted	+218	$380.95	$83K	1,300 direct	Filing · EDGAR
Dec 8, 2022	Sale under a 10b5-1 plan	−218	$779.00	$170K	1,082 direct	Filing · EDGAR
Dec 8, 2022	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−218			4,741 direct	Filing · EDGAR
Sep 9, 2022	Option or RSU exercised or converted	+609	$376.69	$229K	1,691 direct	Filing · EDGAR
Sep 9, 2022	Sale under a 10b5-1 plan	−609	$741.00	$451K	1,082 direct	Filing · EDGAR
Sep 9, 2022	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−609			610 direct	Filing · EDGAR
Sep 8, 2022	Option or RSU exercised or converted	+1,279	$391.92	$501K	2,361 direct	Filing · EDGAR
Sep 8, 2022	Sale under a 10b5-1 plan	−1,279	$705.00	$902K	1,082 direct	Filing · EDGAR
Sep 8, 2022	Option or RSU exercised or converted	+1,279	$391.92	$501K	2,361 direct	Filing · EDGAR
Sep 8, 2022	Sale under a 10b5-1 plan	−1,279	$686.99	$879K	1,082 direct	Filing · EDGAR

35 earlier transactions are in the filing list below.

Cidara Therapeutics CDTX Director · filings 2021 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 7, 2026	Returned to the company	−15	$221.50	$3K	0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−1,750			0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−875			0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−1,400			0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−2,125			0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−2,125			0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−16,000			0 direct	Filing · EDGAR
Jan 7, 2026	Returned to the company Stock Option (right to buy)	−11,100			0 direct	Filing · EDGAR
Jun 18, 2025	Grant or award from the company Stock Option (right to buy)	+11,100			11,100 direct	Filing · EDGAR
Dec 17, 2024	Grant or award from the company Stock Option (right to buy)	+16,000			16,000 direct	Filing · EDGAR
Jul 18, 2024	Grant or award from the company Stock Option (right to buy)	+2,125			2,125 direct	Filing · EDGAR
Jun 22, 2023	Grant or award from the company Stock Option (right to buy)	+42,500			42,500 direct	Filing · EDGAR
Jun 22, 2022	Grant or award from the company Stock Option (right to buy)	+28,000			28,000 direct	Filing · EDGAR
Jun 23, 2021	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Jan 22, 2021	Grant or award from the company Stock Option (right to buy)	+35,000			35,000 direct	Filing · EDGAR

Kaleido Biosciences Director · filings 2019 to 2021

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 30, 2021	Grant or award from the company Stock Option (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 30, 2020	Grant or award from the company Stock Option (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR

All 91 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 30, 2026	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 30, 2026	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 8, 2026	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Mar 31, 2026	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jan 8, 2026	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 7, 2026	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Jan 7, 2026	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 6, 2026	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 2, 2026	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Nov 24, 2025	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Nov 20, 2025	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Sep 30, 2025	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 30, 2025	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 18, 2025	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
May 14, 2025	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Apr 1, 2025	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jan 6, 2025	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 2, 2025	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Dec 19, 2024	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Sep 30, 2024	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Aug 19, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 15, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 5, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 2, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jul 19, 2024	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Jun 28, 2024	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 25, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 24, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 10, 2024	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 7, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 5, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Apr 2, 2024	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Feb 26, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Feb 26, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 31, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 30, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 4, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 3, 2024	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Dec 29, 2023	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Dec 14, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Dec 13, 2023	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Oct 3, 2023	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Aug 23, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 21, 2023	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 11, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 10, 2023	Form 144	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 30, 2023	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 26, 2023	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 23, 2023	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Mar 31, 2023	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Mar 27, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Feb 7, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 5, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 3, 2023	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Dec 12, 2022	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Sep 30, 2022	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Sep 12, 2022	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 30, 2022	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 24, 2022	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Jun 24, 2022	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Apr 11, 2022	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Apr 1, 2022	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Apr 1, 2022	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jan 5, 2022	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 3, 2022	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Sep 30, 2021	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Aug 17, 2021	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 6, 2021	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jul 2, 2021	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jul 1, 2021	Form 4	Kaleido Biosciences	Filing · EDGAR
Jun 30, 2021	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 29, 2021	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jun 24, 2021	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Apr 2, 2021	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jan 25, 2021	Form 4	Cidara Therapeutics CDTX	Filing · EDGAR
Jan 25, 2021	Form 3	Cidara Therapeutics CDTX	Filing · EDGAR
Jan 5, 2021	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 4, 2021	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Oct 2, 2020	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Sep 23, 2020	Form 4	Royalty Pharma RPRX	Filing · EDGAR
Jul 1, 2020	Form 4	Kaleido Biosciences	Filing · EDGAR
Jun 22, 2020	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 15, 2020	Form 3	Royalty Pharma RPRX	Filing · EDGAR
Jun 5, 2020	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 6, 2020	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Feb 27, 2019	Form 3	Kaleido Biosciences	Filing · EDGAR
Jan 4, 2019	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 3, 2018	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jan 4, 2017	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Sep 12, 2016	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Sep 12, 2016	Form 3	Regeneron Pharmaceuticals REGN	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 1:00 AM ET. The filing on SEC.gov is the record.